The role of thrombospondin 1 on intestinal inflammation and carcinogenesis

Biomarker Insights

Volumn 2008, Issue 3, 2008, Pages 171-178

  Gutierrez, Linda S ^a  

^a WILKES UNIVERSITY   (United States)

Author keywords

Angiogenesis; ApcMin+mouse; CD36; Inflammatory bowel disease; Transforming growth factor beta 1

Indexed keywords

ANGIOCIDIN; ANTINEOPLASTIC AGENT; CD36 ANTIGEN; DEXTRAN SULFATE; FIBRINOGEN; FIBRONECTIN; HEPARAN SULFATE; INTEGRIN; IRINOTECAN; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NITRIC OXIDE; PROTEOGLYCAN; SCAVENGER RECEPTOR; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAIN TUMOR; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; COLON CANCER; CROHN DISEASE; DOWN REGULATION; DRUG BINDING; DRUG EFFICACY; ENTERITIS; GENE EXPRESSION REGULATION; GENOTYPE; HUMAN; LEUKOCYTE ACTIVATION; LOW DRUG DOSE; LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEOPLASM; NONHUMAN; OSTEOSARCOMA; REVIEW; TUMOR GROWTH; ULCERATIVE COLITIS; UPREGULATION;

EID: 41949112312     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s630     Document Type: Review

References (75)

1. Hussain, S.P., Hofseth, L.J. and Harris, C.C. 2003. Radical causes of cancer. Nat. Rev. Cancer, 3(4):276-85.
2. Seril, D.N., Liao, J., Yang, G.Y. and Yang, C.S. 2003. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis, 24(3):353-62.
3. Steele, V.E. 2003. Current mechanistic approaches to the chemoprevention of cancer. J. Biochem. Mol. Biol., 36(1):78-81.
4. Shacter, E. and Weitzman, S.A. 2002. Chronic inflammation and cancer. Oncology, 16(2):217-26.
5. Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., Nakamura, Y., White, R., Smits, A.M. and Bos, J.L. 1988. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319(9):525-32.
6. Russel, M. and Stockbrügger, R.W. 1996. Epidemiology of inflammatory bowel disease: and update. Scand. J. Gastroenterol., 31:417-27.
7. Ekbom, A., Helmick, C., Zack, M. and Adami, H. 1990. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med., 323:1229-33.
8. Ritland, R. and Gendler, J. 1999. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis, 20(1):51-8.
9. Folkman, J. 1992. The role of angiogenesis in tumor growth. Semin. Cancer Biol., 3(2):65-71.
10. Danese, S., Dejana, E. and Fiocchi, C. 2007. Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J. Immunol., 178(10):6017-22.
11. Pober, J.S. and Sessa, W.C. 2007. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol., 10:803-15.
12. Abeyama, K., Stern, D.M., Ito, Y., Kawahara, K., Yoshimoto, Y., Tanaka, M., Uchimura, T., Ida, N., Yamazaki, Y., Yamada, S., Yamamoto, Y., Yamamoto, H., Iino, S., Taniguchi, N. and Maruyama, I. 2005. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest, 115(5):1267-74.
13. Lawler, J. 2000. The functions of thrombospondin-1 and-2. Curr. Opin. Cell Biol., 12(5):634-40.
14. Bornstein, P. 2001. Thrombospondins as matricellular modulators of cell function. J. Clin. Invest., 107(8):929-34.
15. Iruela-Arispe, M.L., Liska, D.J., Sage, E.H. and Bornstein, P. 1993. Differential expression of thrombospondin 1, 2, and 3 during murine development. Dev. Dyn., 197:40-56.
16. Murphy-Ullrich, J.E. and Mosher, D. 1985. Localization of thrombospondin in clot formed in situ. Blood, 66:1098-104.
17. Bornstein, P., O'Rourke, K., Wikstrom, K., Wolf, F.W., Katz, R., Li, P. and Dixit, V.M. 1991. A second, expressed thrompospondin gene (Thbs2) exists in the mouse genome. J. Biol. Chem., 266:12821-4.
18. Chandrasekaran, S., Guo, N.H., Rodrigues, R.G., Kaiser, J. and Roberts, D.D. 1999. Pro-adhesive and Chemotactic Activities of Thrombospondin-1 for Breast Carcinoma Cells Are Mediated by 31 Integrin and Regulated by Insulin-like Growth Factor-1 and CD98. J. Biol. Chem., 274(16):11408-16.
19. Silverstein, R.L., Nachman, R.L., Pannell, R., Gurewich, V. and Harpel, P.C. 1990. Thrombospondin forms complexes with single-chain and two-chain forms of urokinase. J. Biol. Chem., 265(19):11289-94.
20. Silverstein, R.L., Leung, L., Harpel, P.C. and Nachman, R.L. 1984. Complex formation of platelets thrombospondin with plasminogen: modulation of activation by tissue activator. J. Clin. Invest, 74:1625-33.
21. Hogg, P.J., Owensby, D.A., Mosher, D.F., Misenheimer, T.M. and Chestterman, C.N. 1993. Thrombospondin is a tight-binding competitive inhibitor of neutrophil elastase. J. Biol. Chem., 268:7139-46.
22. Jimenez, B., Volpert, Q., Crawford, S.E., Febbraio, M., Silverstein, R.L. and Bouck, N. 2000. Signal leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med., 6(1):41-8.
23. Schultz-Cherry, S., Chen, H., Mosher, D.F., Misenheimer, T.M., Krutzsch, H.C., Roberts, D.D. and Murphy-Ullrich, J.E. 1995. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J. Biol. Chem., 270(13):7304-10.
24. Murphy-Ullrich, J.E., Schultz-Cherry, S. and Höök, M. 1992. Transforming growth factor-complexes with thrombospondin. Mol. Biol., Cell, 3:181-8.
25. Crawford, S.E., Stellmach, V, Murphy-Ullrich, J.E., Ribeiro, S.M.F., Lawler, J., Hynes, R.O., Boivin, G.P. and Bouck, N. 1998. Thrombospondin-1 is a majpr activator of TGF-1 in vivo. Cell., 93:1159-70.
26. Febbraio, M.H.D. and Silverstein, R.L. 2001. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Clin. Invest., 108(6):785-91.
27. Dawson, D.W., Pearce, S.F., Zhong, R., Silverstein, R.L., Frazier, W.A. and Bouck, N.P. 1997. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell. Biol., 138(3):707-17.
28. Yamauchi, Y., Kuroki, M., Imakiire, T., Abe, H., Uchida, H., Beppu, R., Yamashita, Y., Kuroki, M. and Shirakusa, T. 2002. Thrombospondin-1 differentially regulates release of IL-6 and IL-10 by human monocytic cell line U937. Biochem. Biophys. Res. Commun., 290(5):1551-7.
29. Iruela-Arispe, M.L., Lombardo, M., Krutzsch, H.C., Lawler, J. and Roberts, D.D. 1999. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation, 100(13):1423-31.
30. Vogel, T., Guo, N.H., Krutzsch, H.C., Blake, D.A., Hartman, J., Mendelovitz, S., Panet, A. and Roberts, D.D. 1993. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J. Cell. Biochem., 53(1):74-84.
31. Lawler, J., Miao, W., Duquette, M., Bouck, N., Bronson, R.T. and Hynes, R.O. 2001. Thrombospondin-1 Gene Expression Affects Survival an Tumor Spectrum of p53Deficient Mice. Am. J. Pathol., 159(5):1949-5.
32. Kohonen-Corish, M.R., Daniel, J.J., te Riele, H., Buffinton, G.D. and Dahlstrom, J.E. 2002. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors. Cancer Res., 62(7):2092-7.
33. Roberts, D.D., Isenberg, J.S., Ridnour, L.A. and Wink, D.A. 2007. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin. Cancer Res., 13(3):795-8.
34. Yamauchi, M., Imajoh-Ohmi, S. and Shibuya, M. 2007. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci., 98(9):1491-7.
35. Short, S.M., Derrien, A., Narsimhan, R.P., Lawler, J., Ingber, D.E. and Zetter, B.R. 2005. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J. Cell Biol., 168(4):643-53.
36. Lawler, J., Weinstein, R. and Hynes, R.O. 1988. Cell attachment to thrombospondin: the role of ARG-GLY.-ASP, calcium, and integrin receptors. J. Cell Biol., 107(6 Pt 1):2351-61.
37. Gao, A.G., Lindberg, F.P., Finn, M.B., Blystone, S.D., Brown, E.J. and Frazier, W.A. 1996. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J. Biol. Chem., 271(1):21-4.
38. Vallejo, A.N., Mügge, L.O., Klimiuk, P.A., Weyand, C.M. and Goronzy, J.J. 2000. Central role of thrombospondin-1 in the activation and clonal expansion of cells. J. Immunol., 164:2947-54.
39. Li, Z., Calzada, M.J., Sipes, J.M., Cashel, J.A., Krutzsch, H.C., Annis, D.S., Mosher, D.F. and Roberts, D.D. 2002. Interactions of thrombospondins with {alpha}4 {beta} 1 integrin and CD47 differentially modulate T cell behavior. J. Cell Biol., 157:509-51.
40. Grimbert, P., Bouguermouh, S., Baba, N., Nakajima, T., Allakhverdi, Z., Braun, D., Saito, H., Rubio, M., Delespesse, G. and Sarfati, M. 2006. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25 -T cells in response to inflammation. J. Immunol., 177 (6):3534-41.
41. Lamy, L., Foussat, A., Brown, E.J., Bornstein, P., Ticchioni, M. and Bernard, A. 2007. Interactions between CD47 and thrombospondin reduce inflammation. J. Immunol., 178(9):5930-9.
42. Koch, A.E., Szekanecz, Z., Friedman, J., Haines, G.K., Langman, C.B. and Bouck, N.P. 1998. Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. J. Clin. Immunol. Immunopathol., 86(2):199-208.
43. Lawler, J., Sunday, M., Thibert, V., Duquette, M., George, E.L., Rayburn, H. and Hynes, R.O. 1998. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J. Clin. Invest, 101(5):982.
44. Beck, P.L., Rosenberg, I.M., Xavier, R.J., Koh, T., Wong, J.F. and Podolsky, D.K. 2003. Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells. Am. J. Pathol., 162(2):597-608.
45. Kulkarni, A.B., Thyagarajan, T. and Letterio, J.J. 2002. Function of cytokines within the TGF-beta superfamily as determined from transgenic and gene knockout studies in mice. Curr. Mol. Med., 2(3):303-27.
46. Leveen, P., Larsson, J., Ehinger, M., Cilio, C.M., Sundler, M., Sjostrand, L.J., Holmdahl, R. and Karlsson, S. 2002. Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. Blood, 100(2):560-8.
47. Jo, W.S., Mizukami, Y., Duerr, E.M., Zukerberg, L.R. and Chung, D.C. 2005. Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis. Cancer Biol. Ther., 4(12):1361-6.
48. Punekar, S., Zak, S., Kalter, V.G., Dobransky, L., Punekar, I., Lawler, J.V. and Gutierrez, L.S. 2008. Thrombospondin 1 and its mimetic peptide ABT-510, decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology, 75 (in press):
49. Chidlow, J.H. Jr, Langston, W., Greer, J.J., Ostanin, D., Abdelbaqi, M., Houghton, J., Senthilkumar, A., Shukla, D., Mazar, A.P., Grisham, M.B. and Kevil, C.G. 2006. Differential angiogenic regulation of experimental colitis. Am. J. Pathol., 169(6):2014-30.
50. Rennemeier, C., Hammerschmidt, S., Niemann, S., Inamura, S., Zähringer, U. and Kehrel, B.E. 2007. Thrombospondin-1 promotes cellular adherence of gram-positive pathogens via recognition of peptidoglycan. FASEB. J., 21(12):3118-32.
51. Calabi, E., Calabi, F., Phillips, A.D. and Fairweather, N.F. 2002. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect. Immuno, 70(10):5770-8.
52. Sharma, A., Pidcock, K.A. and Gutierrez, L.S. Thrombospondin genetic deficiency limits fecal coliform density in C57BL/6J. mice. 2007. Abstracts from the 2006 CCFA National Research and Clinical Conference, 5th Annual Advances in the Inflammatory Bowel Diseases, Dec. 1-3, 2006, Miami, FL. Inflamm. Bowel Dis., 13(S5):653.
53. Sargiannidou, I., Zhou, J. and Tuszynski, G.P. 2001. The role of thrombospondin-1 in tumor progression. Exp. Biol. Med., 226(8):726-33.
54. Varani, J., Dixit, V.M., Fligiel, S.E., McKeever, P.E. and Carey, T.E. 1986. Thrombospondininduced attachment and spreading of human squamous carcinoma cells. Exp. Cell Res., 167(2):376-90.
55. Grossfeld, G.D., Ginsberg, D.A., Stein, J.P., Bochner, B.H., Esrig, D., Groshen, S., Dunn, M., Nichols, P.W., Taylor, C.R., Skinner, D.G. and Cote, R.J. 1997. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. Natl. Cancer Inst., 89(3):219-27.
56. Ohtani, Y., Kijima, H., Dowaki, S., Kashiwagi, H., Tobita, K., Tsukui, M., Tanaka, Y., Tsuchida, T., Tokunaga, T., Yamazaki, H., Nakamura, M., Ueyama, Y., Tanaka, M., Tajima, T. and Makuuchi, H. 1999. Stromal expression of thrombospondin-1 is correlated with growth and metastasis of human gallbladder carcinoma. Int. J. Oncol., 15(3):453-7.
57. Streit, M., Velasco, P., Brown, L.F., Skobe, M., Richard, L., Riccardi, L., Lawler, J. and Detmar, M. 1999. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am. J. Pathol., 155:441-52.
58. Weinstat-Saslow, D.L., Zabrenetzky, V.S., VanHoutte, K., Frazier, W.A., Roberts, D.D. and Steeg, P.S. 1994. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma celline reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res., 54(24):6504-11.
59. Rodriguez-Manzaneque, J.C., Lane, T.F., Ortega, M.A., Hynes, R.O., Lawler, J. and Iruela-Arispe, M.L. 2001. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Proc. Natl. Acad. Sci., U.S.A. 98(2):12485-90.
60. Maeda, K., Nishiguchi, Y., Kang, S.M., Yashiro, M., Onoda, N., Sawada, T., Ishikawa, T. and Hirakawa, K. 2001. Expression of thrombospondin-1 inversely correlated with tumor vascularity amd hematogenous metastasis in colon cancer. Oncol. Rep., 8:763-6.
61. Miao, W.M., Seng, W.L., Duquette, M., Lawler, P., Laus, C. and Lawler, J. 2001. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res., 61(21):7830-9.
62. Gutierrez, L.S., Suckow, M., Lawler, J., Ploplis, V.A. and Castellino, F.J. 2003. Thrombospondin-1 a regulator of adenoma growth an carcinoma progression in the ApcMin/+ mouse model. Carcinogenesis, 24(2):199-207.
63. Engle, S.J., Ormsby, I., Pawlowski, S., Boivin, G.P., Croft, J., Balish, E. and Doetschman, T. 2002. Elimination of colon cancer in germ-free transforming growth factor beta 1 deficient mice. Cancer Res., 62(22):6362-6.
64. Gong, J., Ammanamanchi, S., Ko, T.C. and Brattain, M.G. 2003. Transforming Growth Factor beta1 Increases the Stability of p21/ WAF1/ CIP1 Protein and Inbibits CDK2 Kinase Activity in Human Colon Carcinoma FET Cells. Cancer Res., 63(12):3340-6.
65. Miyanaga, K., Kato, Y., Nakamura, T., Matsumura, M., Amaya, H., Horiuchi, T., Chiba, Y. and Tanaka, K. 2002. Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res., 22(6c):3941-8.
66. Iddings, D.M., Koda, E.A., Grewal, S.S., Parker, R., Saha, S. and Bilchik, A. 2007. Association of angiogenesis markers with lymph node metastasis in early colorectal cancer. Arch. Surg., 142(8):738-44.
67. Zak, S., Treven, J., Nash, N. and Gutierrez, L.S. 2008. Lack of thrombospondin 1 increases angiogenesis in a model of chronic inflammatory bowel disease. Int. J. Colorectal Dis., 23(3):297-304.
68. Danese, S., Sans, M., Spencer, D.M., Beck, I., Donate, F., Plunkett, M.L., de la Motte, C., Redline, R., Shaw, D.E., Levine, A.D., Mazar, A.P. and Fiocchi, C. 2007. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut, 56(6):855-62.
69. Allegrini, G., Goulette, F.A., Darnowski, J.W. and Calabresi, P. 2004. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother. Pharmacol., 53(3):261-6.
70. Anderson, J.C., Grammer, J.R., Wang, W., Nabors, L.B., Henkin, J., Stewart, J.E. Jr. and Gladson, C.L. 2007. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol. Ther., 6(3):454-62.
71. Joyce, D.J., Gutierrez, L.S., Mulji, G. and Castellino, F.J. 2006. Evaluation of the Thrombospondin-1 analogue ABT-510 in the APCMin/+ mouse intestinal adenoma model. J. Clin. Oncol., 24, No. 18S (Suppl):13545.
72. Zhou, J., Rothman, V.L., Sargiannidou, I., Dimitrov, S., Qiu, C., Smith, E., Sheffield, J., Sharma, M. and Tuszynski, G.P. 2004. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1. J. Cell. Biochem., 92(1):125-46.
73. Liebig, C., Agarwal, N., Ayala, G.E., Verstovsek, G., Tuszynski, G.P. and Albo, D. 2007. Angiocidin inhibitory peptides decrease tumor burden in a murine colon cancer model. J. Surg. Res., 142(2):320-6.
74. Greenberg, M.E., Sun, M., Zhang, R., Febbraio, M., Silverstein, R. and Hazen, S.L. 2006. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J. Exp. Med., 203(12):2613-25.
75. Isenberg, J.S., Yu, C. and Roberts, D.D. 2008. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem. Pharmacol., 75(4):875-82.